The difference between the mean operative delays in the two groups was therefore 43 hours (95% confidence interval 41-35 to 44-45 h; t=6 0 143 df; p<O-OOOl). Despite a slight difference in the median ages for groups A and B (80 (range 47-%) and 82 (range 69-93), respectively) age distributions were similar. Typical reasons for delay included operator fatigue, delay in diagnosis, lack of theatre time, industrial action, and lack of patient's consent.
The difference between the mean operative delays in the two groups was therefore 43 hours (95% confidence interval 41-35 to 44-45 h; t=6 0 143 df; p<O-OOOl). Despite a slight difference in the median ages for groups A and B (80 (range 47-%) and 82 (range 69-93), respectively) age distributions were similar. Typical reasons for delay included operator fatigue, delay in diagnosis, lack of theatre time, industrial action, and lack of patient's consent.
Discussion
This retrospective -study suggests that the longer an otherwise fit patient has to wait for her hip fracture to be treated the less she will progress after discharge, regardless of her social circumstances. Many hospitals use trauma list systems, patients admitted one day being held over to the-next before undergoing surgery. Previous work has shown that delays of 1348 hours are not necessarily detrimental to patients' wellbeing.2 Such work, however, emphasises the delay between admission and surgery rather than between injury and operation, the two observations often being widely different. Some of our patients had languished at home for several days before being admitted to hospital; thus in these cases there was a-short interval between admission and surgery but an unacceptable delay between injury and surgery.
Loss of independence is perhaps the most important social problem relating to patients with fractures of the femoral neck, resulting in blocked beds and overloading ofsocial and pnrmary care services. What then should be done to avoid this for the elderly patient who arrives in the accident and emergency department with a hip fracture? We believe that if she is otherwise fit every effort should be made for her to undergo surgery at the earliest opportunity. To include such patients in a standard trauma listsystem, however convenient it may be for surgeons, anaesthetists, and administrators, is to exacerbate a situation that is already out of control. Over 30 months 9292 consecutive patients admitted to nine coronary care units with suspected myocardial infarction were considered for admission to a randomised double blind study comparing the effect on mortality ofnifedipine 10 mg four times a day with that ofplacebo. Among the 4801 patients excluded from the study the overall one month fatality rate was 18-2% and the one month fatality rate in those with definite myocardial infarction 2688%. A total of4491 patients fulfilled the entry criteria and were randomly allocated to nifedipine or placebo immediately after assessment in the coronary care unit. Roughly 64% of patients in both treatment groups sustained an acute myocardial infarction. The overall one month fatalty rates were 6-3% in the placebo treated group and 677% in the nifedipine treated group. Most of the deaths occurred in patients with an in hospital
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Introduction
Nifedipine is a substituted dihydropyridine with calcium chanel blocking properties.' Compared with verapamil it has very little cardiac electrophysiological effect.2 In experimental myocardial infarction in animals pretreatment with nifedipine in a dose carefully regulated to avoid a large fall in blood pressure and reflex tachycardia causes an increase in coronary blood flow in both normally perfused and ischaemic areas of the heart, delays the release of cytoplasmic enzymes and the intracellular accumulation ofcalcium, preserves intracellular stores ofadenosine triphosphate, and reduces infarct size.m Nifedipine is active during periods of ischaemia and also during subsequent reperfusion.3 This has led to speculation that the drug may have a "cardioprotective" action in man.
In angina nifedipine has been shown to increase coronary perfusion and decrease afterload with minimal decrease in contractility' 8 and is thereby thought to stabilise the imbalance between oxygen supply and oxygen demand. Roberts and coworkers have shown that nifedipine produces similar haemodynamic effects in patients with acute infarction, suggesting that in this condition also the drug may be capable of improving a myocardial oxygen deficiency.' Nifedipine also inhibits coronary artery spasm" " and exerts a mild antiaggregatory effect on plateets,'2 both effects that have been implicated in myocardial infarction. '3 The study by Roberts et al also suggested that treatment with nifedipine within 12 hours ofan infarct is safe provided that the dose is judiciously regulated to prevent hypotension. Immediately after assessment in the coronary care unit eligible patients were randomised in a double blind manner to receive placebo or a 10 mg nifedipine capsule. The first capsule was given sublingually and the patient reassessed at four hours. If at that time the systolic blood pressure exceeded 90 mm Hg and the heart rate was less than 120 beats/min a second sublingual capsule was given; otherwise the second dose was withheld and the patient reassessed at six hours and again at eight hours if necessary. If at eight hours after the first sublingual capsule the blood pressure and heart rate were still outside these limits the patient was withdrawn from the study but documentation was continued and the patient followed up to 28 days.
After the second sublingual dose six hourly oral treatment with placebo or 10 mg nifedipine capsules was begun a minimum of two hours and a maximum of eight hours later according to the above haemodynamic criteria. Oral treatment was continued until review in the outpatient clinic roughly 28 days after admission to the coronary care unit. During this time patients could be withdrawn at the discretion of the participating physician for the following reasons: systolic blood pressure persistently less than 90 mm Hg; persistent tachycardia > 120/min; heart failure needing vasodilator or inotropic drugs; need for calcium channel blocking drugs; presumed "side effects"; refusal by the patient to continue with the trial medication; or another definite non-cardiac cause for the chest pain established.
Patients who had taken a 0 blocker within 48 hours before admission to the coronary care unit were randomised to placebo or nifedipine capsules separately from the rest. Pi Blockers could be continued or withdrawn at the discretion of the consultant physician. It was agreed, however, that P blockers given for secondary prophylaxis against further myocardial infarction would not be started in patients included in the trial until their 28 day clinic assessment. It was also agreed to adopt as closely as possible a common therapeutic policy for patients included and excluded during the 28 day study period. Thus no routine anticoagulant or antiarrhythmic drugs were prescribed, digoxin was used only for controlling the ventricular rate in atrial fibrillation, and early mobilisation and discharge from hospital was encouraged.
CLINICAL ASSESSMENT AFTER ADMISSION TO STUDY
Pulse rate and systemic blood pressure (phase V diastolic) were recorded every 15 minutes for the first two hours, every 30 minutes for the next four hours, then two hourly until the second sublingual dose, and thereafter twice daily in all included patients. All patients had continuous electrocardiogram monitoring during their stay in the coronary care unit, and activities of three sets of "cardiac" enzymes (one of which had to be serum aspartate transaminase) were estimated during the first three days together with three 12 lead electrocardiograms. Patients were grouped by the local investigator into one of the following five categories ofinfarct and non-infarct chest pain.
Patients with definite myocardial infarction had a convincing history accompanied by pathological Q waves in the electrocardiogram and peak enzyme activities exceeding twice the upper limit of normal for that hospital's laboratory.
Patients with probable myocardial infarction had a convincing history plus either pathological Q waves in the electrocardiogram or a rise in cardiac enzyme activities to more than twice the upper limit of normal.
Patients with possible myocardial infarction had a convincing history accompanied by electrocardiographic abnormalities that were not diagnostic of myocardial infarction and by an increase in cardiac enzyme activities that did not exceed twice the upper limit of normal.
Patients with ischaemic heart disease had a history of previous myocardial infarction or angina but without sequential electrocardiographic or enzyme changes during the present admission.
Patients with chest pain of unknown cause did not have a history of previous myocardial infarction or angina or sequential electrocardiographic or enzyme changes, and no alternative definite cause for their pain was diagnosed.
All major clinical events which occurred during the 28 day study period were recorded in both included and excluded patients. In addition, we recorded at 28 days any readmissions, current symptoms, and current and subsequent treatment. All patients included in the trial were subsequently followed up for the next 11 months.
The following information was collected about deaths which occurred in the 28 day study period: whether observed or unobserved; whether in or out of hospital; timing of death from onset of original or new main symptoms; and causes of death according to all available evidence, aided by necropsy reports where available.
DATA HANDLING Demographic and clinical data were recorded in special booklets by the participating consultant physicians and their research assistants. All completed data forms were reviewed in the department ofmedicine at University Hospital, Nottingham, before being sent for computerisation in the department of mathematics at Nottingham University. From there regular reports were sent to an independent ethical review committee. The committee had the power to recommend that the study should be discontinued at any time for the following reasons: (a) if before 100 deaths had been notified there was a benefit to either group and the 99% confidence interval did not embrace zero; (b) if at any time thereafter the 95% confidence interval did not embrace a 10% effect (for a beneficial trend) or zero (for an adverse trend); and (c) ifwhen the number ofentrants to the trial approached the precalculated target it appeared that there was little chance of detecting an unequivocally positive effect.
SAMPLE SIZE
Based on our earlier findings we calculated that the overall one month mortality in untreated patients admitted with suspected myocardial infarction to an early entry trial would be 10%. To detect a 30% reduction in mortality in the group given active treatment-that is, a mortality of 7%-the minimum sample size required would be 1820 in each group, assuming that 2c=0 05 and =0 01. After the first few months of the study it became clear that the overall one month mortality was lower than expected and we were thus permitted to redefine our sample size based on an overall death rate of 8%.
DRUG SUPPLIES
Active and placebo capsules were supplied to the pharmacies of the participating hospitals by Bayer UK Ltd as blister packs already randomised in blocks of six. A senior pharmacist at each hospital held a code break in the event of emergency. I) .
Clinical course-The time from onset of major symptoms to the receipt of the first sublingual capsule was similar in the two treatment groups. Of patients in the two groups combined, 1441 (32%) received their first capsule within four hours, 3048 (68%) within eight hours, 3645 (81%) within 12 hours, and most of the remainder within the next four hours. The clinical course and treatment requirements in hospital were also similar (table II) , as was the in hospital diagnostic classification, 64% of patients in each group (1442 placebo, 1429 nifedipine) being diagnosed as having had an acute myocardial infarction (table III) .
Withdrawals-Of the patients allocated to nifedipine and placebo, 608 (27%) and 572 (25%) respectively were withdrawn from treatment before the 28th day. (14 5) 342 (15 3 Other diagnosis 94 99 (44) physician or general practitioner, 229 (5%) had discontinued treatment of their own accord, and in 70 (2%) compliance was not recorded. There were no differences between the nifedipine and placebo treatment groups. Deaths-Altogether 150 (6-7%) of the patients allocated to nifedipine died in the first 28 days compared with 141 (6 3%) of those allocated to placebo. There was a higher proportion of deaths among patients withdrawn from their allocated treatments than among those who continued but there were no differences between the nifedipine and placebo groups in this respect (figure). The excess deaths among the patients who were withdrawn occurred particularly in those whose reason for withdrawal was persistent hypotension or tachycardia or severe heart failure. By intention to treat analysis there was thus an increase in overall mortality of 7% in the nifedipine group (approximate 95% confidence interval +30% to -16% hospital diagnosis of acute myocardial infarction. The 28 day fatality rate of patients with myocardial infarction was thus 10-2% (146/1429) for the nifedipine group and 9 3% (134/1442) for the placebo group. Of the remaining 11 deaths (3-8%) during the study, seven occurred in patients with an in hospital diagnosis of ischaemic heart disease, three in patients with other diagnoses, and one in a patient with chest pain of unknown cause. Five of the patients with ischaemic heart disease died suddenly, four of them at home and one in hospital (proved ruptured aortic aneurysm). One died during coronary artery bypass grafting and one was readmitted in congestive cardiac failure and died of intractable ventricular fibrillation. All three 1207 diagnosed as having a myocardial infarction in hospital was lower in the [1 blocker groups irrespective of trial randomization, the infarct fatality rate was higher (table V) . There were no definite adverse interactions, however, between nifedipine and previous treatment with f3 blockers. Time to treatment and outcome-There was no difference in the delay between the onset ofsymptoms and the initiation oftrial medication between the placebo and nifedipine groups. Post hoc stratification by time, however, suggested that patients receiving nifedipine after eight hours did slightly worse than those given placebo (table VI) .
Others-The expected increase in mortality with age was seen in both By 30 minutes after beginning treatment the average systolic blood pressure was roughly 5 mm Hg lower in the nifedipine group and the average diastolic pressure roughly 4 mm Hg lower. Heart rate was higher in the nifedipine group by an average of 3 beats/min. These small differences were still discernible at the 28 day assessment.
EXCLUDED PATIENTS
In hospital diagnostic coding was available for 4798 of the 4801 excluded patients. Of these, 2926 (61%) were diagnosed as having an acute myocardial infarction, 1039 (22%) ischaemic heart disease, 374 (8%) chest pain of unknown cause, and 322 (7%) other diagnoses.
The 28 day outcome was unknown for 127 (2-6%) of the total excluded group. Among the 4674 patients for whom complete data were available the overall fatality rate was 18-2% (855 deaths) as compared with the 6-5% among patients entered into the nifedipine versus placebo trial. This difference was largely due to a much higher mortality in patients with diagnosed infarcts (786/2926; 26-8%) as compared with the trial placebo group (134/1442; 9-3%) and trial nifedipine group (146/1429; 10-2%), reflecting their older age and poorer cardiovascular state on admission to the coronary care units.
Discussion
During this trial several other clinical studies were reported suggesting that the optimism engendered by animal studies for using calcium channel blocking drugs in myocardial ischaemia was not supported by clinical experience. In a large Danish multicentre study of acute infarction verapamil was given firstly intravenously, then by mouth in a daily dose of 120 mg for six months. Of 3498 patients randomised to verapamil or placebo there was no difference either in the number who progressed to proved myocardial infarction or in the fatality rates at six months. 17 Sirnes et al entered 227 patients with suspected acute myocardial infarction within 12 hours from onset of symptoms to treatment with nifedipine or placebo in a manner comparable to our study.' They found no evidence that nifedipine reduced infarct size as determined by enzyme kinetics. They considered nifedipine to be safe in this setting, however, and its use was associated with a reduction in frusemide requirements during the first four days. This may reflect a beneficial effect of nifedipine on left ventricular function and is in keeping with invasive studies which showed that nifedipine reduced myocardial oxygen requirements and enhanced cardiac and peripheral haemodynamics with subsequent improvement in cardiac output." 9 In our study, however, we saw no difference in the incidence of or treatment for heart failure between the nifedipine and placebo treated patients.
Muller et al screened almost 10000 patients admitted to four coronary care units and ultimately randomised 243 patients with symptoms suggestive ofmyocardial ischaemia ofless than six hours' duration to either placebo or nifedipine 20 mg every four hours for 14 days.2' They found no evidence of a reduced progression from "threatened" to acute myocardial infarction, no difference in cardiac enzyme kinetics in those with proved myocardial infarction, and no difference in mortality at six months. They attributed this neutral effect of nifedipine to the delay between the onset of symptoms and the beginning oftreatment (mean 4-6 hours). We did not randomise patients separately according to time from symptoms but in our much larger study retrospective stratification by time did not disclose a potential advantage in those patients treated early. As with other "cardioprotective" strategies, however, the time interval between symptoms and treatment may be crucial.2 '24 The optimal dose of nifedipine is uncertain. We used a dose schedule and rate of administration which had been shown to result in "therapeutic" plasma concentrations of nifedipine and to be clinically safe, avoiding any large falls in blood pressure. We were, perhaps, unduly worried by the possibility ofan unfavourable fall in systolic blood pressure or increase in heart rate that a larger dose might have caused. In a recent study Gottlieb et al gave placebo or oral nifedipine 120 mg daily for 10 days to 30 patients with acute myocardial infarction.-' Using two dimensional echocardiography they found a significant reduction in what they termed early infarct expansion. They attributed this ostensibly advantageous effect of nifedipine to the modest reduction in systolic blood pressure (mean 9 mm Hg). In our study using a much smaller daily dose we found a mean fall in systolic blood pressure of 5 mm Hg.
At the inception of the study we were also concerned about a potentially deleterious interaction between nifedipine and (3 blockers?"&7 Hence we randomised patients separately according to whether or not they were already takfing ,B blocking drugs on admission to the coronary care units. In the event we saw no cause for concern, though we cannot say whether the same would have occurred had we used a larger dose of nifedipine. Furthermore, our patients were acutely withdrawn from nifedipine, either for specified reasons ofprotocol or at the end of the 28 day treatment period, and we saw no evidence of an acute withdrawal syndrome as described for verapamil and diltiazem.2' Though the withdrawal rates in our study were comparable for the two treatment groups, we saw two interesting patterns. The first was an increase in unwanted effects among the patients withdrawn from nifedipine, though most of these were non-specific and not worrying, and the second was the substantial difference in numbers of patients withdrawn from trial medication in order to be treated electively with a calcium channel blocking drug because ofpersistent angina. This accords with the known antanginal effect ofnifedipine and, because of its relative safety with regard to left ventricular function, may commend it for this purpose in patients in the early postinfarction phase.
